Krasner CN, Campos SM, Young CL, Chadda KR, et al. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2021 Jul 6. pii: S0090-8258(21)00532.
PMID: 34243976